| |
rPBP3c
|
Bla
d
|
Proportions (%) of isolates and patients
|
---|
Groups of isolatesb
|
n
|
n
|
%
|
n
|
%
|
Anatomical sites
|
Age groups
|
Hospitalizede
|
---|
| | | | | |
Eye
|
Ear
|
Respiratory
|
0-3
|
≥50
| |
---|
Resistant group
|
177
|
116
|
66
|
16
|
9
|
28
|
10
|
58
|
44
|
24
|
33
|
Susceptible group
|
19
|
0
|
0
|
0
|
0
|
21
|
32
|
42
|
68
|
5
|
11
|
Remaining isolates
|
599
|
0f
|
0f
|
60g
|
10g
|
19
|
15
|
63
|
41
|
22
|
23
|
Original population
|
795h
|
116
|
15
|
76
|
10
|
21
|
14
|
62
|
43
|
22
|
25
|
-
aNORM 2007 surveillance population [33], consisting of consecutive routine isolates from patients with eye, ear and respiratory tract infections.
-
bSee text and Figure 1 for definition of the study groups (Resistant group and Susceptible group).
-
cPBP3-mediated resistance (see Table 1).
-
dBeta-lactamase positive.
-
eProportions of patients hospitalized at the time of sampling.
-
fAssuming that all rPBP3 isolates were selected for the Resistant group.
-
gAs reported by the primary laboratories.
-
hThirteen isolates were selected for the Resistant group but excluded for various reasons (see Figure 1).